Black tea consumption and serum lipid profiles in Saudi women: A cross-sectional study in Saudi Arabia

Nutrition Research

Volumn 23, Issue 11, 2003, Pages 1515-1526

  Hakim, Iman A ^a   Alsaif, Mohammed A ^a   Aloud, Amal ^a   Alduwaihy, Mansour ^b   Al Rubeaan, Khalid ^b   Al Nuaim, Abdul Rahman ^b   Al Attas, Omar S ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Black tea; Lipids; Prevention; Saudi Arabia; Women

Indexed keywords

BLACK TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; FEMALE; FOOD INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK BENEFIT ANALYSIS; SAUDI ARABIA; SEX DIFFERENCE; TEA;

CAMELLIA SINENSIS;

EID: 0142057408     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0271-5317(03)00176-3     Document Type: Article

References (45)

1. Hokanson JE, Austin MA. Plasma triglycerides level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: meta-analysis of the population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
2. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-9.
3. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. Circulation 1999;100:475-82.
4. Assmann G, Gullen P, Schulte H. The Munster Heart Study (PROCAM)-results of follow up at 8 years. Eur Heart J 1998;19:A2-A11.
5. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl. 2):S1-S26.
6. Legato MJ. Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy. Am J Cardiol 2000;86(Suppl 1):15-8.
7. Al-Nuaim RA. High prevalence of metabolic risk factors for cardiovascular diseases among Saudi population, aged 30-64 years. Int J Cardiol 1997;62:227-35.
8. Al-Nuaim AR, Mirdad S, al-Rubeaan K, al-Mazrou Y, al-Attas O, al-Daghari N, Khoja T. Population-based epidemiological study on characteristics of risk factors of hyper-cholesterolemia in Saudi Arabia. Int J Cardiol 1997;62:47-54.
9. Rosenberg L, Palmer JR, Kelly JP, Kaufman DW, Shapiro S. Coffee drinking and non-fatal myocardial infarction in men under 55 years of age. Am J Epidemiol 1988;28:570-8.
10. Brown CA, Bolton-Smith C, Woodward M, Tunstall-Pedoe H. Coffee and tea consumption and the prevalence of coronary heart disease in men and women: results from the Scottish Heart Health Study. J Epidemiol Community Health 1993;47:171-5.
11. Rimm ER, Katan MB, Ascherio A, Stampfer M, Willet W. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996;125:384-9.
12. Sesso HD, Gaziano JM, Buring JE, Hennekens CH. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999;149:162-7.
13. Stensvold I, Tverdal A, Solvoll K, Foss OP. Tea consumption relationship to cholesterol, blood pressure, and coronary and total mortality. Prev Med 1992;21:546-53.
14. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996;312:478-81.
15. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic S. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 1995;155:381-6.
16. Kono S, Shinchi Ikeda N, Yanai F, Imanishi K. Green tea consumption and serum lipid profiles: a cross-sectional study in Northern Kyushu, Japan. Prev Med 1992;21:526-31.
17. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
18. Milaat W. Public health around the world: Saudi Arabia. Public Health Med 1999;1:34-8.
19. Stata Corp. Stata statistical software, intercooled stata, release 6.0, College Station, TX: Stata Corporation, 1999.
20. Hollman PCH, Hertog MCL, Katan MB. Role of dietary flavonoids in protection against cancer and coronary heart disease. Biochem Soc Trans 1996;24:785-9.
21. Katan MB. Flavonoids and heart disease. Am J Clin Nutr 1997;65:1542-3.
22. Muldoon MF, Kritchevsky SB. Flavonoids and heart disease. BMJ 1996;312:458-9.
23. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329-45.
24. Assmann G, Carmena R, Cullen P, Fruchart J-C, Lewis B, Mancini M, Olsson APR, Pometta D, Tikkanen M. International Task Force for Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk. The scientific background for the primary and secondary prevention of coronary heart disease. A worldwide view. Nutr Metab Cardiovasc Dis 1998;8:205-71.
25. Wood D, De Backer G, Faergemann O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
26. Geleijnse JM, Launer LJ, Hofman A, Pols HA, Witteman JC. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. Arch Int Med 1999;159:2170-4.
27. Green MS, Harari G. Association of serum lipoproteins and health-related habits with coffee and tea consumption in free-living subjects examined in the Israeli CORDIS Study. Prev Med 1992;21:532-45.
28. Klatsky AL, Petitti DB, Armstrong MA, Friedman GD. Coffee, tea and cholesterol. Am J Cardiol 1985;55:577-8.
29. Curb JD, Reed DM, Kautz JA, Yano K. Coffee, caffeine, and serum cholesterol in Japanese men in Hawaii. Am J Epidemiol 1986;123:648-55.
30. Davis BR, Curb JD, Borhani NO, Prineas RJ, Molteni A. Coffee consumption and serum cholesterol in the Hypertension Detection and Follow-up Program. Am J Epidemiol 1988;128:124-36.
31. Carson CA, Cauley JA, Caggiula AW. Relation of caffeine intake to blood lipids in elderly women. Am J Epidemiol 1993;138:94-100.
32. Kark JD, Friedlander Y, Kaufmann NA, Stein Y. Coffee, tea, and plasma cholesterol: the Jerusalem Lipid Research Clinic prevalence study. BMJ 1985;291:699-704.
33. Hertog MGL, Hollman PCH, Putte B. Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juices. J Agric Food Chem 1993;41:1242-6.
34. Hakim IA, Harris RB, Weisgerber U. Tea intake and skin squamous cell carcinoma: influence of type of tea beverages. Cancer Epidemiol Biomarkers Prev 2000;9:727-31.
35. Hakim IA, Weisgerber UM, Harris RB, Balentine D, van-Mierlo CAJ, Paetau-Robinson I. Preparation, composition and consumption patterns of tea-based beverages in Arizona. Nutr Res 2000;20:1715-24.
36. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988;62:1109-12.
37. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravaststin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57.
38. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastafin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1625-6.
39. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
40. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9.
41. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl J Med 1995;333:1301-7.
42. Expert panel on detection evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J Am Med Assoc 2001;285:2486-97.
43. Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis 1988;8:207-11.
44. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990;31:1149-72.
45. Spiller RC. Cholesterol, fiber, and bile acids. Lancet 1996;347:415-6.